An Efficacy and Safety Study of Palonosetron in Preventing Chemotherapy-Induced Nausea and Vomiting (CINV) in the Chinese Cancer Patients

Inclusion Criteria

• •Male or female, age ranging from 18 yrs to 70 yrs, with histologically or cytologically confirmed malignant disease
• •naive to chemotherapy or nonnaive with an interval of at least 14 days to the last one
• •Karnofsky index more than 70% and anticipated survival time more than 90 days
• •Scheduled to receive any of the following cytotoxic agents based combination chemotherapy (epirubicin 60 mg/m2, or cisplatin 75 mg/m2) on study Day 1 and the chemotherapy should be accomplished on study Day 1
• •No emetic episodes and antiemetic medication during the 24 hours preceding chemotherapy administration
• •Adequate organ functions(No impairment to renal, hepatic, cardiac or bone marrow function )
• •Use of reliable contraceptive measures (for females of childbearing potential) and negative pregnancy test at baseline visit
• •Provision of written informed consent